Protalix BioTherapeutics, Inc. (DE)
As of Oct 22, 2026, Protalix BioTherapeutics, Inc. (DE) is in Stage 2, the uptrend phase, now in week 12 (since Aug 3, 2026). It closed at $2.57, 18.4% below its 52-week high and above its 200-day average, which is rising.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based p… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is PLX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PLX among Biotechnology137th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …137 | PLX | Stage 2 · wk 12 | 70 | −8.2% |
Protalix BioTherapeutics, Inc. (DE): quick answers
What stage is Protalix BioTherapeutics, Inc. (DE) in?
As of Oct 22, 2026, Protalix BioTherapeutics, Inc. (DE) (PLX) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 3, 2026 and is in week 12. What the four stages mean
Is Protalix BioTherapeutics, Inc. (DE) in an uptrend?
Yes. Protalix BioTherapeutics, Inc. (DE) is in a Stage 2 uptrend. It trades 7.2% above its 200-day average, which is rising.
How far is Protalix BioTherapeutics, Inc. (DE) from its 52-week high?
Protalix BioTherapeutics, Inc. (DE) closed at $2.57 on Oct 22, 2026, 18.4% below its 52-week high of $3.15. Its 52-week low is $1.67.
How has Protalix BioTherapeutics, Inc. (DE) performed over the past year?
As of Oct 22, 2026, Protalix BioTherapeutics, Inc. (DE) is up 20.1% over the past year and up 47.7% so far in 2026.
Which sector and industry is Protalix BioTherapeutics, Inc. (DE) in?
Protalix BioTherapeutics, Inc. (DE) is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.